Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
Sign Up to like & getrecommendations! Published in 2018 at "Translational Oncology"
DOI: 10.1016/j.tranon.2018.01.002
Abstract: OBJECTIVE: A previous phase-2 trial to assess the addition of Endostar to gemcitabine and cisplatin (GC) chemotherapy showed that it improves prognosis in metastatic nasopharyngeal carcinoma (M-NPC) but the study cohort was small. We wished… read more here.
Keywords: chemotherapy; cisplatin chemotherapy; gemcitabine cisplatin; day ... See more keywords
Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
Sign Up to like & getrecommendations! Published in 2021 at "Translational Oncology"
DOI: 10.1016/j.tranon.2021.101187
Abstract: Highlights • Locoregional radiotherapy can prolong OS for patients with de novo metastatic nasopharyngeal carcinoma.• Nasopharyngeal carcinoma patients with oligometastic disease can benefit from locoregional radiotherapy rather than polymetastatic disease. read more here.
Keywords: metastatic nasopharyngeal; nasopharyngeal carcinoma; locoregional radiotherapy; novo metastatic ... See more keywords
Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.357
Abstract: Background:The majority of published studies in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are single-arm trials. Reliable modelling of progression-free survival (PFS) and overall survival (OS) outcomes, therefore, is difficult. This study aim to analyse existent… read more here.
Keywords: recurrent metastatic; months model; metastatic nasopharyngeal; nasopharyngeal carcinoma ... See more keywords
Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/6860413
Abstract: Background Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine's effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine's tolerability… read more here.
Keywords: metastatic nasopharyngeal; capecitabine; capecitabine monotherapy; treatment ... See more keywords
Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/7233559
Abstract: Objective To compare the efficacy and safety of gemcitabine plus cisplatin (GP) and 5-fluorouracil plus cisplatin (PF) for metastatic nasopharyngeal carcinoma. Methods The clinical trials of GP and PF in the treatment of metastatic nasopharyngeal… read more here.
Keywords: nasopharyngeal carcinoma; plus cisplatin; metastatic nasopharyngeal; analysis ... See more keywords
Stereotactic body radiotherapy to extend the clinical benefit of PD-1 inhibitors in recurrent/metastatic nasopharyngeal carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18013
Abstract: e18013Background: Emerging evidences have showed that immune checkpoint inhibitors lead to durable responses in a variety of advanced cancers, including recurrent/metastatic nasopharyngeal carcinom... read more here.
Keywords: recurrent metastatic; body radiotherapy; stereotactic body; radiotherapy extend ... See more keywords
GEM20110714: Final overall survival results of the phase III study of first-line gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6521
Abstract: 6521Background: GEM20110714, the first randomized, phase III study (NCT01528618) of systemic chemotherapy in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC), reported significant reduc... read more here.
Keywords: recurrent metastatic; phase iii; plus cisplatin; iii study ... See more keywords
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01450
Abstract: PURPOSE Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC). METHODS This single-arm, Simon two-stage study enrolled… read more here.
Keywords: nasopharyngeal carcinoma; metastatic nasopharyngeal; single arm; patients recurrent ... See more keywords
Systemic immune-inflammation index as a prognostic marker in patients with newly diagnosed metastatic nasopharyngeal carcinoma: a propensity score-matched study
Sign Up to like & getrecommendations! Published in 2019 at "Translational Cancer Research"
DOI: 10.21037/tcr.2019.09.25
Abstract: Background Systemic immune-inflammation index (SII) is significantly associated with poor survival in variety of cancers. However, SII has not yet been investigated in patients with newly diagnosed metastatic nasopharyngeal carcinoma (mNPC). Thus, our aim is… read more here.
Keywords: analysis; nasopharyngeal carcinoma; patients newly; metastatic nasopharyngeal ... See more keywords
Association of Epstein-Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0010
Abstract: Objectives: The relevant biomarkers in predicting maintenance therapy (MT) outcomes in metastatic nasopharyngeal carcinoma (NPC) are yet unclear. Patients & methods: Metastatic NPC patients were randomly divided into MT (S1-MT) and non-MT groups. The association of… read more here.
Keywords: nasopharyngeal carcinoma; metastatic nasopharyngeal; dna saa; dna ... See more keywords